Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Published:2017-03-22 Issue:7 Volume:7 Page:704-715
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Juric Dejan,Krop Ian,Ramanathan Ramesh K.,Wilson Timothy R.,Ware Joseph A.,Sanabria Bohorquez Sandra M.,Savage Heidi M.,Sampath Deepak,Salphati Laurent,Lin Ray S.,Jin Huan,Parmar Hema,Hsu Jerry Y.,Von Hoff Daniel D.,Baselga José

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications;Seminars in Cancer Biology;2024-11

2. A Perspective of PI3K/AKT/mTOR Pathway Inhibitors to Overcome Drug-resistance in Breast Cancer Therapy;Current Medicinal Chemistry;2024-08-21

3. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions;Molecular Cancer;2024-08-10

4. Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer;Cancer Chemotherapy and Pharmacology;2024-06-27

5. Molecular pathways and targeted therapies in head and neck cancers pathogenesis;Frontiers in Oncology;2024-06-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP